Histone deacetylase inhibitors: molecular mechanisms of action (Q36908440)

17 August 2017

1 reference

title

Histone deacetylase inhibitors: molecular mechanisms of action (English)

1 reference

17 August 2017

Xu WS

1 reference

17 August 2017

Parmigiani RB

series ordinal

1 reference

17 August 2017

Marks PA

series ordinal

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

page(s)

5541-5552

1 reference

Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

1 reference

7 January 2021

Modulating molecular chaperone Hsp90 functions through reversible acetylation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

The Sir2 family of protein deacetylases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Anticancer activities of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

HDAC6-p97/VCP controlled polyubiquitin chain turnover

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Exploiting tumour hypoxia in cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone deacetylase inhibitors specifically kill nonproliferating tumour cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone acetylation-mediated regulation of genes in leukaemic cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

HDAC inhibitors overcome first hurdle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Defining the role of gene regulation in resistance to HDAC inhibitors--mechanisms beyond P-glycoprotein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Acetylation and deacetylation of non-histone proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

p15INK4b in HDAC inhibitor‐induced growth arrest

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Identification of novel isoform-selective inhibitors within class I histone deacetylases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

HDAC6 is a microtubule-associated deacetylase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Proteomic analysis of organ-specific post-translational lysine-acetylation and -methylation in mice by use of anti-acetyllysine and -methyllysine mouse monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Cytochrome C-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Cytoplasmic dynein/dynactin mediates the assembly of aggresomes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Substrate and functional diversity of lysine acetylation revealed by a proteomics survey

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Effects of histone deacetylase inhibitors on HIF-1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Thioredoxin and related molecules--from biology to health and disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone deacetylation in epigenetics: an attractive target for anticancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone deacetylase inhibitors: discovery and development as anticancer agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: Molecular and clinical studies employing hybrid polar compounds

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone Deacetylase Inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

The role of the redox protein thioredoxin in cell growth and cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone deacetylase inhibitors in clinical development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Histone deacetylase inhibitors: insights into mechanisms of lethality

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Hsp90: a novel target for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

A phase II study of depsipeptide in refractory metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Cell-cycle inhibitors: three families united by a common cause

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

From discovery to the coming generation of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

New stem cell center at Cornell

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Two catalytic domains are required for protein deacetylation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Acetylation by p300 regulates nuclear localization and function of the transcriptional corepressor CtBP2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Characterization of the two catalytic domains in histone deacetylase 6.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210620

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210620

1 reference

17 August 2017

1 reference